SCHEMBL22540920

SCHEMBL22540920

NC(=O)c1cc(N)cc(C2CC2)n1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
SRC P12931 1/20 0.40
POLB P06746 2/20 0.37
CDK8 P49336 1/20 0.36
CDK19 Q9BWU1 1/20 0.36
DGAT1 O75907 4/20 0.35
NQO2 P16083 2/20 0.35
HRH4 Q9H3N8 1/20 0.34
GRM2 Q14416 3/20 0.34
SYK P43405 1/20 0.33
PIM1 P11309 3/20 0.33
KCNH2 Q12809 3/20 0.33
PIM2 Q9P1W9 3/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
PKMYT1 Q99640 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18544575 0.86 POLB (0.44) SRCPOLBHRH4
SCHEMBL17844394 0.85 SCD (0.37) LMNASRCPOLB
SCHEMBL6103259 0.80 NQO2 (0.45) SRCPOLBCDK8CDK19NQO2
SCHEMBL30825359 0.78 LMNA (0.38) LMNAPOLBCDK8CDK19DGAT1
SCHEMBL9636253 0.78 LMNA (0.56) LMNANQO2GRM2PIM1PIM2
SCHEMBL17837370 0.78 KDM4E (0.48)
SCHEMBL3925158 0.74 CNR2 (0.50) POLBDGAT1SYKPIM1KCNH2
SCHEMBL23811375 0.72 HRH4 (0.40) POLBHRH4
SCHEMBL30097519 0.72 LMNA (0.50) LMNANQO2GRM2PIM1PIM2
SCHEMBL23413382 0.72 LMNA (0.50) LMNANQO2GRM2PIM1PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023081486-A1 TOLL-LIKE RECEPTOR THERAPY COMBINATIONS WITH CBL-B INHIBITOR COMPOUNDS NURIX THERAPEUTICS, INC. (US) 2023-05-11 WO disclosed
WO-2020264398-A1 SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF NURIX THERAPEUTICS, INC. (US) 2020-12-30 WO disclosed
WO-2020236654-A1 CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF NURIX THERAPEUTICS, INC. (US) 2020-11-26 WO disclosed
WO-2020210508-A1 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS NURIX THERAPEUTICS, INC. (US) 2020-10-15 WO disclosed